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During pregnancy, malaria infection in the mother can cause low birth weight and 
result in poor pregnancy outcomes. The choice of antimalarial drugs is critical in 
Democratic Republic of the Congo because of its malaria burden which is among the 
highest in sub-Saharan Africa. Artemisinin –based combination therapies regimen is 
recommended by World Health Organization for uncomplicated malaria in second or third 
trimester of pregnancy to treat uncomplicated malaria in pregnancy. However, the choice 
of drug to treat malaria during pregnancy depends on the prescriber knowledge, 
socioeconomic status, adherence and drugs availability in the health facility and all these 
may impact on pregnancy outcomes such as preterm delivery, stillbirth, abortion and 
newborn weight.  This study aimed to examine the association between Artemisinin –based 
combination therapy regimen and low birth weight including pregnancy outcomes in Mont 
Amba district, Kinshasa. 
It was based on patient records, cross-sectional, retrospective study in Mont Amba 
District, Kinshasa, from January to December 2018.The study population comprised 
pregnant mothers diagnosed with uncomplicated malaria in second or third trimester whom 
ages vary between 16 and 49. We used patient registries information about antimalarial 
drugs received, antenatal care visits, socioeconomic status, origin of those pregnant 
mothers and delivery information such as term, stillbirth, baby’s weight, sex, from a 
secondary level health facility. 
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We sampled three hundred and sixty- four mothers and excluded all mothers aged 
below 16 or above 49, who did not deliver in the same health facility. Finally, two hundred 
and sixty-four mothers remained for our study. We categorized them in ACTs and non- 
ACTs groups according the antimalarial regimen they received. Continuous variables were 
calculated using two-sample Student’s t-test. Categorical variables were analyzed using 
Chi-square or Fisher’s exact test, as appropriate. Multivariate analysis was performed by 
logistic regression. All p-values were 2-tailed, with p<0.05 considered to be statistically 
significant. Statistical analyses were carried out by SPSS® version 25. Among 264 
patients, there were 102(38.6%) using artemisinin –based combination therapies and 
162(61.4%) using non- artemisinin –based combination therapies. Among these patients, 
134(50.8%) were young women aged 20 to 29 years and majority of women came from 
Kisenso commune 215(81.4%). There were no significant differences in maternal age 
(28.3±6.4 vs. 27.7±6.3; p=0.782), outcome of pregnancy (term:72(70.6%) vs. 104(64.2%); 
p=0.283, preterm:28(27.5%) vs. 58(35.8%); p=0.159, stillbirth :2(2.0%) vs. 6(3.7%); 
p=0.715), infantile birth weight (3211.2g±504.0 vs. 3087.0±546); p=0.133, socioeconomic 
status (96(94.1%) vs. 160(98.8%); p=0.058), and antennal care (87(85.3%) vs 121(76.1%); 
p=0.072) between artemisinin –based combination therapies group and non- artemisinin –
based combination therapies group. In the multivariate logistic regression, there was no 
significant difference in birth weight of infants born to women who received artemisinin –
based combination therapies and those who did not (odds ratio, 1.208; 95% confidence 
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interval, 0.490-2.976; p=0.682). The current study results suggest that there is no impact of 
ACTs or non- ACTs treatment regimen on newborn weight preterm, abortion, and stillbirth  
 




A. Background  
Malaria infection during pregnancy remains dangerous for mother and newborn 
and can lead to infant low birth weight, maternal anemia, miscarriage, and stillbirth. [Renee 
burger, Anna M. Van]. From the year 2006, the World Health Organization has 
recommended the use of Artemisinin-based combination therapy (ACT) for the treatment 
of uncomplicated falciparum malaria in the second and third trimester of pregnancy1.  
ACTs had been adopted as national policy for first-line treatment in 79 of 88 countries 
where Plasmodium falciparum is endemic by the year 20132 ; although, it has not always 
been clear whether this policy is also applicable to the treatment of pregnant women in the 
second and third trimester. In DRC and other countries where the policy has been adopted, 
many health workers continue to provide oral quinine, the drug recommended for treatment 
in the first trimester3.  Over the past 2 decades, several studies have compared the efficacy 
and safety of ACTs to quinine and other non-ACTs in the second and third trimester4, but 
individual studies often lack the power to draw definitive conclusions. Therefore, this study 
aimed to determine the association between ACTs regimen and low birth weight in DRC. 
DRC is the second largest country by area in Africa (after Algeria) and the third 
most populated. A national census has not been conducted since 1984, but the Ministry of 
Health estimates the population to be 89,284,658 in 2017 and 91,873,913 in 2018, with the 
majority living in rural areas. The annual population growth rate is 3.2%. It shares borders 
with nine countries: Republic of Congo (Brazzaville), Central African Republic, Burundi, 
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South Sudan, Uganda, Rwanda, Tanzania, Zambia, and Angola, the last five of which are 
also PMI focus countries. The DRC sits on over 25 trillion dollars of minerals, which has 
the potential to significantly improve the economic situation of its residents, but this 
benefits only a small number of people and companies5. The country ranks 176 out of 188 
countries in the world on the 2016 Human Development Index; an estimated 63% of the 
population lives on less than $1 per day. According to the 2013-14 Demographic and 
Health Survey (DHS), the under-five mortality rate is 104 per 1.000 live births, a substantial 
reduction from the previous rate of 158 per 1.000 (Multiple Indicator Cluster Survey 
2010)5. 
There is still much to learn about the epidemiological stratification of malaria in 
the DRC, but generally the country can be divided into three epidemiological zones.  
The mountainous zones of North Kivu are at an altitude of 1.000 to 1.500 meters. 
In this zone, malaria is hypo-endemic. The transmission season is very short and there can 
sometimes be no transmission for years. Malaria natural immunity is difficult to acquire, 
thus malaria occurs in the form of an epidemic and severe malaria affects all age groups. 
In the tropical zone, transmission is seasonal and highest during the rainy season, 
which lasts five to eight months. Malaria mortality is also highest during the rainy season. 
Populations living in this zone are exposed to 60 to 400 infectious bites per person per year. 
Malaria natural acquired immunity starts building up around 10 years old, and severe 
malaria mostly affects younger and older children. 
3 
 
In the equatorial zone, transmission is intense and occurs year-round. People are 
exposed to up to 100 infectious bites per person per year and start building up natural 
immunity at an earlier age. Thirty to fifty percent of fevers in children under five years of 
age are due to malaria, and severe malaria is mainly observed in this age group. 
It is estimated that 97% of the population lives in zones with stable malaria 
transmission lasting 8 to 12 months per year. The highest levels of transmission occur in 
zones situated in the north and west of the country.  It is known throughout tropical Africa 
that the greatest burden of malaria morbidity and mortality falls on pregnant women and 
children under five years of age. In the DRC, malaria is linked with high mortality and 
morbidity, accounting for 39% of all outpatient visits and for 39% of deaths in 2014. Due 
to the fact that the majority of the population lives in high transmission zones, it has been 
estimated that the DRC accounts for 9% of all malaria cases and 10% of all malaria deaths 
in sub-Saharan Africa5, 6. 
The 2013-14 DHS, which constituted a representative sample for the eleven (11) 
old provinces, five (5) demonstrated that national malaria parasite prevalence in children 
6-59 months to be between 23% and 34% depending upon the diagnostic test used: 22.7% 
for microscopy, 30.9% for RDTs, and 34.1% for polymerase chain reaction (PCR). 
However, the prevalence was found to be higher for those living in rural areas compared to 
urban; prevalence was highest in Orientale province and lowest in North Kivu (for all 
diagnostic methods). When comparing the PCR and microscopy results in the DHS 
supplemental malaria report shows that prevalence using PCR is approximately 50% higher 
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than with microscopy because it detects much lower levels of parasitemia; these findings 
are consistent with other studies. Molecular analyses suggest that mono-infection with 
Plasmodium ovale or Plasmodium malariae is rare (estimated at 0.6-1.7%). The survey 
also showed that 6.2% of Congolese children aged 6-59 months had severe anemia that 
could be associated with malaria (8.0 g/dl or less).  
The National Malaria Control Strategic Plan for 2016-2020 divides the country 
into four strata based on parasite prevalence.  The 2013-2014 DHS was conducted prior to 
the territorial reform that sub-divided the former 11 provinces into 26 new provinces. 
Provincial stratification based on malaria parasite prevalence, DRC-DHS II 2013-14 Strata 
Parasite Main Provinces % Population prevalence determinant I. ≤5% Mountain zone - 
hypo endemic Nord Kivu 8%5. 
There is still controversial opinion on the use of Artemisinin combination therapies 
(ACTs), the most efficacious antimalarial drugs available, are the recommended first-line 
treatment for Plasmodium falciparum malaria except in the first trimester of pregnancy1, 
7. Preclinical studies have shown that artemisinin based combination therapies are 
embryotoxic and can induce fetal death and congenital anomalies at doses close to the 
therapeutic range in multiple animal species8. Artemisinin derivatives in rodents cause 
embryolethality as well as cardiovascular (ventricular septal and vessel defects) and 
skeletal defects9. Embryolethality was observed in monkey following prolonged treatment 
(12 to 20 d), but there were no malformations. The artemisinin embryotoxic effect occurs 
through depletion of embryonic erythroblasts8. It is unknown how findings from animal 
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studies would translate in humans because the mechanism of teratogenicity and the drug 
sensitive period may differ significantly in humans10.  
The last review by the World Health Organization (WHO) dates from 2006, when 
evidence on 170 human first-trimester artemisinin treatments was reassuring but 
insufficient to inform policy change11. That is why, quinine remains the recommended 
treatment for uncomplicated P. falciparum malaria in the first trimester. Presently, 
artemisinin derivatives are recommended in the first trimester only if quinine cannot be 
used or in cases of severe malaria where the benefit outweighs the potential risk. 
It is estimated that each year over 30 million women become pregnant in malaria’s 
prone areas in Africa, with most living in areas of stable malaria transmission12. Although 
the vast majority of women with malaria infections during pregnancy remain 
asymptomatic, infection increases the risk of maternal anemia and delivering a low-birth-
weight (LBW) baby. LBW (2,500 g) is an important risk factor for infant mortality, and 
this review focuses on the impact of malaria during pregnancy on LBW and subsequent 
infant mortality in sub-Saharan Africa. There have been many papers describing the impact 
of malaria during pregnancy (and, more recently, attempts to quantify this burden 
(Steketee, R. W., B. L, 2001. The burden of malaria in pregnancy in malaria – endemic 
areas). However, there remains a poor understanding of the effects under different levels 
of transmission and in different gravidity groups. It is frequently reported that 
primigravidae and secundigravidae are the most at risk, and many of the literature on the 
burden of malaria during pregnancy have focused on women of these gravidities. However, 
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there is an increasing recognition that women of higher gravidities may also be at risk, 
particularly in areas of high transmission levels13. 
B. Objectives of the study 
1. General objective 
To determine the association between ACTs regimen and low birth weight in Mont 
Amba, Kinshasa, in DRC. 
2. Specific objectives 
1. To determine the impact of ACTs versus non-ACTs treatment on baby and 
pregnancy outcomes, 
2. To recommend appropriate treatment regimen during pregnancy in Mont 




II. LITERATURE REVIEW 
1. Malaria in pregnancy situation in DRC 
Recent Demographic and Health Survey (DHS) showed some evidence of 
improvement in the coverage of MIP interventions in the DRC. Use of ANC services 
remained relatively stable between the 2007 and 2013-14 DHS surveys, with 79% and 86% 
of women having at least two ANC visits, respectively. However, IPTp coverage only 
improved slightly over that same period, increasing from 5% in 2007 to 14% in 2013 for 
women receiving at least two doses of SP. Over the same period, use of bed nets among 
pregnant women increased substantially, from 7% in 2007 to 60% in 2013. 
Last year PMI supported the implementation of MIP interventions in 178 health 
zones in 9 provinces. In the past 12 months, 492,174 treatments of SP were distributed to 
service delivery points. With FY 2018 funds, PMI will continue to supply ITNs and SP and 
to support training and supervision to ensure that providers are aware of and implementing 
the current guidelines regarding IPTp dosing and timing. SBCC activities will continue at 
both health facility and community levels and include counseling strategies on the use of 
ITNs during pregnancy, the importance of early attendance at ANC and obtaining SP at 




2. Case Management of malaria in DRC 
Diagnosis and Treatment  
The DRC National Malaria Control Strategic Plan states that by the end of 2020, 
80% of fever cases should be tested for malaria, and 100% of those who test positive should 
receive appropriate treatment according to national guidelines. The national malaria case 
management guidelines and accompanying training package were revised and validated in 
April 2017 by the Disease Control Directorate. These updated guidelines largely 
conformed to WHO guidelines and standards, with the exception of age groups for pre-
referral treatment with rectal articulate. For diagnosis, the guidelines state that all febrile 
patients should be tested for malaria by either microscopy or RDT. Microscopy is to be 
used at reference hospitals, primarily to monitor patients undergoing treatment for severe 
malaria and to monitor for treatment failure. RDTs are to be used in peripheral health 
centers and at the community level; they may also be used at reference hospitals as needed. 
The guidelines state that each provincial hospital and each general reference hospital should 
have a functioning laboratory to conduct microscopy. Currently, all 26 provincial hospitals 
have a functioning laboratory. For health zones, 393 of the 516 health zones have 
government-run (i.e., public) general reference hospitals and the remaining 123 health 
zones have either a faith-based hospital or a private health facility that serves as the 
reference hospital for the zone. In theory, all health zone general hospitals have at least one 
microscope, but current information about whether or not they are functional is not 
available, including in the PMI zones.  
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For uncomplicated malaria, the country supports two first-line ACT treatments: 
artesunate-amodiaquine (AS/AQ) and artemether-lumefantrine (AL). If one of the two 
first-line ACTs is not available or is poorly tolerated by the patient, the other can be used. 
In practice, AL tends to be primarily used in urban areas because patients have more options 
to obtain it from private pharmacies, while AS/AQ is used in rural areas. In case of 
confirmed treatment failure by microscopy to both first-line ACTs, the patient should be 
given dual therapy of quinine plus clindamycin. In case of a one-time epidemic, the national 
guidelines state that dihydroartemisinin-piperaquine (DP) could be used; for this reason, 
DP is included in the ongoing therapeutic efficacy study (details below).  
For treatment of severe malaria, injectable articulate should be the first treatment 
option, followed by injectable artemether or IV quinine. At peripheral levels, including 
lower-level health facilities and community care sites, pre-referral treatment with rectal 
articulate is national policy, although roll out of training and commodities for pre-referral 
treatment is still underway. The national guidelines did not specify eligible age groups for 
rectal articulate (e.g., less than 6 years old per WHO guidelines) but do provided dosing 
guidelines for age groups of 6-13 years and 14 years and older in addition to children under 
6 years old. With PMI support, the NMCP reviewed this guideline to align with the WHO, 
but decided to limit the use of rectal articulate to children under 5 years of age to line up 
with the information captured by current data collection tools and remain coherent with 
other strategic approaches that target this age group.  
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Care-seeking and treatment in the private sector (including non-profit and faith-
based facilities, for-profit clinics, pharmacies, and drug shops) is widespread. According 
to the 2013-2014 DHS, among children with fever, 49% report seeking care in the public 
sector and 47% in the private sector. The non-profit/faith-based facilities often function 
much like the public-sector facilities in that they report into the routine health information 
system and abide by the national policies. But there are important differences in treatment 
availability in public and private outlets. A research project supported by ACT watch from 
2013 to 2015 in Kinshasa and Katanga provinces included representative “outlet surveys” 
that assessed availability of malaria diagnostics and treatment at service delivery points, 
including public facilities and CHWs, private non-profit and for-profit facilities, regulated 
pharmacies, and unregulated drug shops and retailers. The last survey in 2015 found that 
drug shops represented 69% of outlets in Kinshasa and 59% in Katanga. In Kinshasa, 87% 
of public sector outlets stocked quality-assured ACTs; in Katanga 92% did. In the private 
sector, however, only 22% of private outlets stocked quality-assured ACTs in Kinshasa 
while 53% stocked them in Katanga.8 At the community level, integrated community case 
management (iCCM) is provided at community care sites (sites de soin communautaire). 
According to national guidelines, two volunteer community health workers (relais 
communautaire) are identified for each community care site. One CHW is responsible for 
providing diagnosis, treatment, and referral services while the other focuses on health 
promotion and community mobilization. CHWs are unpaid. Criteria for selection include a 
minimum level of education as well as having an established source of income, separate 
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from their unpaid health activities. Both CHWs are to be trained approximately every two 
to three years in malaria, pneumonia, and diarrhea diagnosis and treatment; this includes 
administration of RDTs, ACTs, and rectal articulate for severe cases. According to national 
guidelines, diagnosis with RDTs and malaria treatment is free for patients of all ages. 
Microscopy incurs a fee and other service provision fees may be applicable for malaria 
patients (e.g., consultation fees, paracetamol).  
Antenatal care in DRC 
It has been demonstrated that early and regular antenatal care attendance is strongly 
associated to better maternal and neonatal outcomes because pregnant women who do so 
fully benefit from its preventive and curative services. To reduce maternal and neonatal 
morbidity and mortality, the World Health Organization (WHO) recommended that 
pregnant women should receive ANC services at least 4 times starting from the first 
trimester of pregnancy. These provided services are used for prevention, early diagnosis, 
and treatment of pregnancy-related problems. In endemic malaria areas, some high-impact 
interventions such as the use of impregnated nets, the prompt management of malaria cases 
and anemia, and the intermittent preventive therapy (IPTp) are implemented to reduce 
malaria burden in pregnancy in areas with stable transmission of Plasmodium falciparum. 
Malaria is the most common parasitic disease in the world caused by Plasmodium and 
transmitted to humans by an infected female Anopheles mosquito. Through its National 
Malaria Control Program, the DRC is committed to achieve by 2015 the prevention of 80% 
of pregnant women. Intermittent preventive therapy (IPTp) is one of the preventive services 
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recommended by the WHO to control this disease. But for this IPTp to be effective it must 
be administered according to standards that are based, on one side, on its early onset before 
20 weeks and, on the other, on the number of recommended doses to be administered. The 
study undertaken by Célestin Ndosimao Nsibu, et all., in 2016 showed that than 22% of 
Congolese pregnant women attend the ANC facilities in the first trimester as reported in 
2010 from the MICS survey and therefore most of the targeted women do not benefit from 
all delivered high-impact interventions. Present recommendations of the WHO impose 4 
doses of IPTp to women during their pregnancy14. 
Antimaalarial and traditional plants used in DRC 
Malaria is the most prevalent parasitic disease and the foremost cause of morbidity 
and mortality in the DRC. For the management of this disease, large Congolese population 
recourses to traditional medicinal plants. To date the efficacy and safety of many of these 
plants have been validated scientifically in rodent malaria models. In order to generate 
scientific evidence of traditional remedies used in the DRC for the management of malaria, 
and show the potential of Congolese plants as a major source of antimalarial drugs, Patrick 
B. Memvanga a, n et all., in 2015 worked on the antiplasmodial and toxicological properties 
of the Congolese antimalarial plants investigated during the period of 1999–2014. In doing 
so, a useful resource for further complementary investigations is presented.  It has been 
proven that approximately 120 extracts and fractions obtained from Congolese medicinal 
plants showed pronounced or good antiplasmodial activity. A number of compounds with 
interesting antiplasmodial properties were also isolated and identified. Some of these 
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compounds constituted new scaffolds for the synthesis of promising antimalarial drugs. 
Interestingly, most of these extracts and compounds possessed high selective activity 
against Plasmodium parasites compared to mammalian cells. The efficacy and safety of 
several plant-derived products was confirmed in mice, and a good correlation was observed 
between in vitro and in vivo antimalarial activity. The formulation of several plant-derived 
products also led to some clinical trials and license of three plant-derived drugs 
(Manalarias, Nsansiphoss, and Quinine Pharmakinas) which are among antimalarial plant 
drugs used during this current study. Antimalarial plants utilized in Congolese traditional 
medicine represent an important source for the discovery and development of new 
antimalarial agents. However, in order to ensure the integration of a larger number of plant-
derived products in the Congolese healthcare system, some parameters and trends should 
be considered in further researches, in agreement with the objectives of the “Traditional 
Medicine Strategy” proposed by the World Health Organization in 2013. Among them, we 
have: evaluation of geographical and seasonal variation, investigation of reproductive 
biology, assessment of prophylactic antimalarial activity, evaluation of natural products as 
adjuvant antioxidant therapy for malaria, development of plant-based combination 





I. MATERIAL AND METHODS 
It was a patient records based, cross-sectional, retrospective study in Mont Amba 
District, Kinshasa, from January to December 2018.The study population comprised 
pregnant mothers diagnosed with uncomplicated malaria in second or third trimester whom 
ages vary between 16 and 49. We used patient registries information about antimalarial 
drugs received, antenatal care visits, socioeconomic status, origin of those pregnant 
mothers and delivery information such as term, stillbirth, baby’s weight, sex, length from 










     Figure 1: Study location general view of the capital city of DRC: Kinshasa16(Source: 





Figure 2: Specific location of study site: Mont Amba District (Matete, Lemba, Limete, 
Kisenso, N’djili, Masina)17 
 
We sampled three hundred and sixty- four mothers and excluded all mothers aged 
below 16 or above 49, who did not deliver in the same health facility. Finally, two hundred 
and sixty-four mothers remained for our study. We categorized them in ACTs and non- 
ACTs groups according the antimalarial regimen they received. Continuous variables were 
calculated using two-sample student’s t-test. Categorical variables were analyzed using 
Chi-square or Fisher’s exact test, as appropriate. Multivariate analysis was performed by 
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logistic regression. All p-values were 2-tailed, with p<0.05 considered to be statistically 
significant. Statistical analyses were carried out by SPSS® version 25. 
Table 1. Different antimalarial treatments received by pregnant mothers                                           
Abbreviation Molecules Firm denominations                 
AS/AQ Artesunate -Amodiaquine ACT tablets 




QUININE (Pharmakinas) Quinine sulfate Quinine® Tablets 













A. General characteristics 
Among 264 patients, there were 102(38.6%) using ACT and 162(61.4%) using 
non-ACT. Among these patients, 134(50.8%) were young women aged 20 to 29 years and 




              Table 2. General characteristics 
Characteristics Numbers (n=264) Percentage 
Age   
<20 years 28 10.6 
20-29 134 50.8 
30-39 93 35.2 
40-49 9 3.4 
Parity   
1 121 45.8 
2 66 25.0 
3 and above 77 29.2 
Origin   
Kisenso 215 81.4 
Lemba 6 2.3 
Limete 2 0.8 
Masina 1 0.4 
Matete 39 14.8 
N’djili 1 0.4 
ANC   
No 53 20.3 
Yes 208 79.7 
Treatment   
Non ACT 162 61.4 
ACT 102 38.6 
Birth weight   
≤2500g 24 9.6 
>2500g 227 90.4 
Newborn sex   
Female 141 55.5 
Male 113 45.5 
Outcome   
Term 178 67.4 
Preterm 86 32.6 
* ANC: Antenatal Care 
*ACTs: Artemisin-based combination therapy 
*Non ACTs: Non Artemisinin based combination therapy   
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B. Comparison of clinical characteristics between ACT and Non-ACT groups 
There were no significant differences in maternal age (28.3±6.4 vs. 27.7±6.3; 
p=0.782), outcome of pregnancy (term:72(70.6%) vs. 104(64.2%); p=0.283, 
preterm:28(27.5%) vs. 58(35.8%); p=0.159, stillbirth:2(2.0%) vs. 6(3.7%); p=0.715), 
infantile birth weight (3211.2g±504.0 vs. 3087.0±546.1), socioeconomic status (96(94.1%) 
vs. 160(98.8%); p=0.058), and antennal care (87(85.3%) vs 121(76.1%); p=0.072) between 
ACT group and non-ACT group as shown in Table 3. 






(N = 162) 
p 
Age (years) 28.3±6.4 27.7±6.3 0.782 
Outcome of pregnancy    
  Term 72(70.6) 104(64.2) 0.283 
  Preterm 28(27.5) 58(35.8) 0.159 
  Abortion 1(1.0) 4(2.5) 0.652 
  Stillbirth 2(2.0) 6(3.7) 0.715 
Continuous variables are shown as means ± standard deviation and medians ± IQR (3rd 
interquartile range-1st interquartile range) and categorical variables as numbers 




C. ACT effect for malaria in pregnancy; Multivariable analysis 
In the multivariate logistic regression, there was no significant difference in birth 
weight of infants born to women who received ACT and those who did not (odds ratio, 
1.208; 95% confidence interval, 0.490-2.976; p=0.682).  
Table 4. ACT effects of malaria in pregnancy; Multivariable analysis 
Variables Odds ratio 95% confidential interval p 
Age (years) 1.014 0.974-1.056 0.493 
Preterm 0.706 0.395-1.262 0.240 
Abortion 0.578 0.060-5.533 0.634 





In this study, we accessed the impact of ACTs on the birth weight of newborns and 
pregnancy outcomes from mothers who suffered from uncomplicated P. falciparum malaria 
during pregnancy in second or third trimester in Mont Amba, in one of highest transmission 
malarial areas in the capital city of Kinshasa. Based on collected data, we aimed to evaluate 
ACTs regimen treatment by itself if it has considerable consequences or not on the newborn 
weight and pregnancy outcomes. And among the non-ACT treatments, we had Quinine and 
traditional plant (Manalaria®) which is not also recommended in the national malaria 
control guideline for the treatment of uncomplicated malaria in DRC during all trimesters 
of pregnancy, however well tolerated and cost effective for most of pregnant women with 
low socio-economic status. This study suggests that there was no statistically significance 
difference among the group of mothers treated with ACTs and Non- ACTs, this means that 
non-ACTs may impact positively pregnancy outcomes and baby’s birth in Mont Amba 
district, being given that it showed no difference on birth weight and pregnancy outcomes. 
These findings are surprising on the fact that those non-ACTs molecules are not suggested 
by malaria control national guidelines. we may suggest the use of non-ACTs as alternative 
to treat uncomplicated malaria in Kinshasa as another option for pregnant women with low 
socioeconomic status we cannot afford ACTs in terms of price and contribute to improved 
access to antimalarial drugs to many mothers during the pregnancy. These current results 
correlate with the study conducted by Kangulu et al., (2014) in semi-rural Kamina in DRC 
which concluded that they are many factors that contribute to low birth weight such as 
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socio-economic status, age less than 18 years and upper than 35 years, ANC, parity and 
prematurity, twin pregnancy and newborn gender (female) are factors that determine birth 
weight., not antimalarial drugs by its self18. 
Similarly, findings of this study also correlate with Tshotethi, et al, 2019 in South 
Africa which showed that the main reason for LBW is preterm delivery, but the etiology of 
preterm delivery remains unknown19. Most authors agree that preterm delivery can be 
caused by medical conditions, and infections like hypertension, malaria, syphilis, and HIV 
infection. A systematic review focusing on developing countries, found a strong association 
between maternal HIV infection and LBW. Contrastingly, a randomized control trial (RCT) 
study in Malawi, failed to find an association between HIV and LBW, even though the 
prevalence of HIV was 26.2%. Therefore, there is conflicting evidence on the relationship 
between HIV infection and LBW. Broek et al, 2014 found that maternal anemia was 
another risk factor for LBW (72.6% versus 64.5% in term pregnancy)20. A multinational 
RCT conducted in sub-Saharan Africa did not find any association between maternal 
anemia and LBW, but maternal age of younger than 19 years and being malnourished were 
associated with LBW. Kumar et al, 2010 compared adverse birth outcomes between 
anemic and non-anemic mothers, and found that maternal hemoglobin status was an 
importance predictor of neonate weight and length. One might argue that malnutrition, 
rather than just anemia, in low-income countries, may affect the weight of neonates. 
Maternal nutrition affects the growth of the baby in utero and the eventual birth weight. 
Maternal infection may also limit the growth of the baby21. 
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In sub-Saharan Africa, maternal malaria infection is an important predictor of 
adverse birth outcomes, including LBW or premature birth. In Congo, 94.5% of LBW 
babies were born to mothers who had malaria. In Malawi, which is a malaria endemic area; 
a RCT showed that 36.4% women who had malaria delivered premature babies, compared 
to 28.5% women who did not have malaria. Other causes that have been reported by 
different authors are non-communicable diseases such as hypertension or diabetes. 
Ngoma et al, 2016 found that teenage mothers had a higher risk of delivering a LBW infant 
than adult mothers (16% versus 9%)22. In contrast, Hoque et. Al, 2008 compared the 
incidence of adverse obstetric and perinatal outcomes of adult mothers to teenage mothers. 
They found that slightly more teenage mothers (14.3%) than adult mothers (13.7%) gave 
birth to LBW babies (P = 0.56)23. Further binary logistic regression showed that teenage 
pregnancy did not predict a LBW outcome. Similarly, in a Pretoria Tertiary Hospital, 
teenage mothers had 17.2% LBW babies compared to 12.6% of adult mothers (P = 0.140) 
and age did not predict LBW. 
Moreover, the findings of this study correlated also with Tshotetsi et all in 2019 
which suggested that Women who attended fewer than five ANC visits were predisposed 
to give birth to low birth weight babies19. Mothers should be encouraged to attend ANC 
visits to detect adverse events like premature rupture of membranes and premature labor to 
avoid low birth weight. Sociodemographic factors associated with LBW were maternal age, 
race of the mother and the residence of the mother. Women older than 20 years (n = 412, 
38.54% of all LBW deliveries) were at risk of LBW delivery (Odds ratio [OR] 1.33, CI 
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1.00 to 1.77). Prenatal factors associated with LBW were ANC attendance, the number of 
ANC visits, not having a syphilis test and a positive HIV status. Almost five percent 
(4.80%) of mothers who did not attend ANC delivered a LBW infant. Mothers who did not 
attend ANC had increased risk (OR 2.65, CI 1.58 to 4.43) of delivering a LBW baby 
compared to those who attended ANC. Women who did not attend ANC, or had missing 
information on the ANC visits had increased risk of delivering a LBW infant (OR 3.76, CI 
2.27 to 6.22) compared to women who attended more than 5 ANC visits. Women who 
attended ANC 1 to 4 times, had an increased risk (OR 1.72 CI 1.22 to 2.43) of delivering 
LBW babies compared to women who attended more than 5 times. Obstetric risk factors 
associated with LBW included women with preeclampsia (OR 3.74, CI 1.04 to 8.84) and 
premature rupture of membranes (PROM) (OR 6.74, CI 2.27 to 20.02). Anaemia, 
hypertension and infections were not significant predictors of LBW deliveries. In adjusted 
analysis, maternal age was associated with LBW (adjusted odds ratio [AOR] 12.20, CI 3.90 
to 38.02) for older women compared to younger women. Women who had fewer than 5 
ANC visits also remained significantly associated with LBW (AOR 1.30, CI 1.06 to 1.61) 
compared to those who attended 5 or more visits. Additionally, PROM remained 
significantly associated with LBW (OR 7.33, CI 2.43 to 22.12). Preterm delivery also 
remained associated with LBW (OR 7.15, CI 5.18 to 9.89) and male infants remained less 




This study had several limitations that need to be taken into consideration. As we 
used data from cross-sectional surveys, our study reported only the association, however, 
it did not make a causal relationship. The study period was short to permit us having strong 
conclusions to be generalized. 
Secondly, we had time constraints, which did not allow us to have a big data sample 
from many years back. 
Finally, we did not have the possibility to get access to the treatments received by 
those mothers during their pregnancy so as to have an idea on which diseases they suffered 
from, excluding malaria that could have an impact on babies’ weight. And also, we did not 
have information on parent’s genetic morphology or body features such as height, size, 







At the end of this study  which allowed us to establish the impact of ACTs and 
non-ACTs on newborn weight  from mothers who contracted falciparum uncomplicated 
malaria and their pregnancy outcomes in Mont Amba district, in DRC, it has been 
demonstrated that ACTs regimen by itself could not explain LBW, abortion, preterm and 
stillbirth from women who delivered after having suffered from malaria in second or third 
trimester , however , there are many other factors or variables to consider such as age of 
the mother , socioeconomic status , parity , type of pregnancy ( twin pregnancy ) , number 
of ANC followed , infections contracted during the pregnancy , genetic features of parents  
can probably explain our study findings . The current study results suggest that there is no 
impact of ACTs or non- ACTs treatment regimen on newborn weight, preterm, abortion, 
and stillbirth. 
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